JP2022514089A5 - - Google Patents
Info
- Publication number
- JP2022514089A5 JP2022514089A5 JP2021535585A JP2021535585A JP2022514089A5 JP 2022514089 A5 JP2022514089 A5 JP 2022514089A5 JP 2021535585 A JP2021535585 A JP 2021535585A JP 2021535585 A JP2021535585 A JP 2021535585A JP 2022514089 A5 JP2022514089 A5 JP 2022514089A5
- Authority
- JP
- Japan
- Prior art keywords
- pathway inhibitor
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- jak1 pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781877P | 2018-12-19 | 2018-12-19 | |
| US62/781,877 | 2018-12-19 | ||
| US201962854801P | 2019-05-30 | 2019-05-30 | |
| US62/854,801 | 2019-05-30 | ||
| US201962901377P | 2019-09-17 | 2019-09-17 | |
| US62/901,377 | 2019-09-17 | ||
| PCT/US2019/067418 WO2020132210A1 (en) | 2018-12-19 | 2019-12-19 | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514089A JP2022514089A (ja) | 2022-02-09 |
| JP2022514089A5 true JP2022514089A5 (https=) | 2022-12-26 |
| JP7624922B2 JP7624922B2 (ja) | 2025-01-31 |
Family
ID=69326646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535585A Active JP7624922B2 (ja) | 2018-12-19 | 2019-12-19 | 胃腸疾患の治療のためのｊａｋ１経路阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11596632B2 (https=) |
| EP (1) | EP3897627A1 (https=) |
| JP (1) | JP7624922B2 (https=) |
| KR (1) | KR20210116487A (https=) |
| CN (1) | CN113692278A (https=) |
| AU (1) | AU2019403304B2 (https=) |
| CA (1) | CA3123596A1 (https=) |
| IL (1) | IL284034A (https=) |
| MA (1) | MA54544A (https=) |
| MX (1) | MX2021007260A (https=) |
| PH (1) | PH12021551455A1 (https=) |
| SG (1) | SG11202106470TA (https=) |
| TW (1) | TWI884142B (https=) |
| UA (1) | UA130221C2 (https=) |
| WO (1) | WO2020132210A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102821964B1 (ko) | 2017-11-03 | 2025-06-19 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 |
| MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CN119080779A (zh) | 2018-08-10 | 2024-12-06 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| JP7624922B2 (ja) | 2018-12-19 | 2025-01-31 | インサイト・コーポレイション | 胃腸疾患の治療のためのｊａｋ１経路阻害剤 |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| WO2024102778A1 (en) * | 2022-11-08 | 2024-05-16 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of itk mediated conditions |
| WO2025144781A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| CN120699157B (zh) * | 2025-07-16 | 2025-12-16 | 安康市中心医院 | 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| HUE033587T2 (hu) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipirazol-származékok mint JAK inhibitorok |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| RS60237B1 (sr) * | 2015-11-24 | 2020-06-30 | Theravance Biopharma R&D Ip Llc | Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti |
| JP2020502126A (ja) * | 2016-12-14 | 2020-01-23 | プロジェニティ， インコーポレイテッド | 消化管疾病のｊａｋ阻害薬による治療 |
| WO2018111327A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of jak inhibitors at the site of gastrointestinal tract disease |
| JP7624922B2 (ja) | 2018-12-19 | 2025-01-31 | インサイト・コーポレイション | 胃腸疾患の治療のためのｊａｋ１経路阻害剤 |
-
2019
- 2019-12-19 JP JP2021535585A patent/JP7624922B2/ja active Active
- 2019-12-19 TW TW108146771A patent/TWI884142B/zh active
- 2019-12-19 MX MX2021007260A patent/MX2021007260A/es unknown
- 2019-12-19 MA MA054544A patent/MA54544A/fr unknown
- 2019-12-19 CA CA3123596A patent/CA3123596A1/en active Pending
- 2019-12-19 WO PCT/US2019/067418 patent/WO2020132210A1/en not_active Ceased
- 2019-12-19 PH PH1/2021/551455A patent/PH12021551455A1/en unknown
- 2019-12-19 CN CN201980090047.2A patent/CN113692278A/zh active Pending
- 2019-12-19 KR KR1020217022692A patent/KR20210116487A/ko active Pending
- 2019-12-19 AU AU2019403304A patent/AU2019403304B2/en active Active
- 2019-12-19 UA UAA202104150A patent/UA130221C2/uk unknown
- 2019-12-19 SG SG11202106470TA patent/SG11202106470TA/en unknown
- 2019-12-19 EP EP19842939.1A patent/EP3897627A1/en active Pending
- 2019-12-19 US US16/720,465 patent/US11596632B2/en active Active
-
2021
- 2021-06-15 IL IL284034A patent/IL284034A/en unknown
-
2023
- 2023-01-31 US US18/103,662 patent/US12150943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514089A5 (https=) | ||
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| KR20230145439A (ko) | Irak4 분해제 및 이의 용도 | |
| US20110053954A1 (en) | Method of treatment and/or prevention of brain, spinal or nerve injury | |
| US8426470B2 (en) | Method for alleviating signs and symptoms of spasticity | |
| UA76417C2 (en) | Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol | |
| JPH05213741A (ja) | デプレニル／ｌ−ドーパ／カルビドーパ含有の医薬組成物 | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2025541249A (ja) | Ｉｒａｋ４分解剤及びその使用 | |
| RU2664422C2 (ru) | Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения | |
| JP2021523220A5 (https=) | ||
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| JP2024531188A5 (https=) | ||
| JP6929860B2 (ja) | 手湿疹の治療 | |
| JP2023528896A5 (https=) | ||
| CA2855503A1 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
| JP2025517509A5 (https=) | ||
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| JP2024516302A5 (https=) | ||
| AU2008257322B2 (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to Parkinson's disease | |
| AU2024229800A1 (en) | Methods of treating essential tremor | |
| WO2019145926A1 (en) | Stable thiamine containing pharmaceutical formulations | |
| US20190062160A1 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| JP2019001830A (ja) | 医薬 |